Sinopharm Group (1099) Fundamentals 2026 — P/E 6.4x, Revenue Analysis | SniperIQ

6.99 on the HKSE. This SniperIQ fundamentals page covers Sinopharm Group's valuation (P/E 6.4x, P/B 0.5x), profitability (net margin 1.2%), revenue (¥575.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Sinopharm Group's market cap?

Sinopharm Group (1099) has a market capitalization of approximately HK$53.0B, trading at HK

6.99 on the HKSE. Market cap moves with the live share price.

What is Sinopharm Group's P/E ratio?

Sinopharm Group's trailing twelve-month P/E ratio is 6.4x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Sinopharm Group?

Sinopharm Group runs a net profit margin of 1.2%, a gross margin of 7.3%, and an operating margin of 2.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Sinopharm Group generate?

Sinopharm Group reported revenue of ¥575.2B for fiscal year 2025, with net income of ¥7.2B and earnings per share (EPS) of 2.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Sinopharm Group pay a dividend?

Sinopharm Group offers a trailing dividend yield of about 4.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Sinopharm Group financially healthy?

Sinopharm Group carries a debt-to-equity ratio of 1.29x and a current ratio of 1.41x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Sinopharm Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sinopharm Group (1099) the key facts are: market cap HK$53.0B, P/E 6.4x, revenue ¥575.2B, 52-week range 15.28-22.34. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.